Every Form 4 that Artelo Biosciences, Inc. (ARTL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ARTL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARTL filings page.
Artelo Biosciences granted director Connie Matsui a stock option covering 136 shares of common stock at an exercise price of $1.15 per share, expiring on July 17, 2036. The option vests 100% on the earlier of the one-year anniversary of the July 17, 2026 Vesting Commencement Date or the day prior to the next annual stockholders’ meeting following that date, contingent on her continued service as a Service Provider.
ARTELO BIOSCIENCES granted director Douglas Blayney a stock option for 136 shares of common stock at an exercise price of $1.15 per share, expiring on July 17, 2036. The option vests 100% on the earlier of one year after the Vesting Commencement Date of July 17, 2026, or the day prior to the next annual stockholders’ meeting, subject to continued service.
Artelo Biosciences director Gregory Reyes received a grant of stock options covering 136 shares of common stock at an exercise price of $1.15 per share, expiring July 17, 2036. All options vest 100% on the earlier of one year after the July 17, 2026 Vesting Commencement Date or the day before the next annual stockholder meeting, subject to his continued service.
Artelo Biosciences director Robert Martin received a grant of 136 stock options to purchase common stock at an exercise price of $1.15 per share. These options expire on July 17, 2036 and will vest 100% on the earlier of the one-year anniversary of the July 17, 2026 Vesting Commencement Date or the day prior to the next annual stockholders’ meeting after that date, subject to his continued service as a Service Provider under the issuer’s plan. Following this award, he holds 136 options from this grant, and the transaction is flagged as made pursuant to a Rule 10b5-1 trading arrangement.
ARTELO BIOSCIENCES, INC. reported that director Steven Kelly received a grant of stock options for 136 shares of common stock at an exercise price of $1.15 per share. The options vest 100% on the earlier of the one-year anniversary of a July 17, 2026 vesting commencement date or the day prior to the next annual stockholder meeting following that date, subject to continued service as a Service Provider, and expire on 2036-07-17.
Artelo Biosciences director Tamara A. Favorito received a grant of stock options covering 136 shares of common stock at an exercise price of $1.15 per share. The options expire on July 17, 2036 and will fully vest, subject to her continuing as a Service Provider, on the earlier of one year after the July 17, 2026 Vesting Commencement Date or the day before the next annual stockholders’ meeting following that date. After this grant, she directly holds 136 stock options.
Artelo Biosciences director Connie Matsui reported receiving a grant of stock options on January 30, 2026. The award covers 292 stock options, each with a $1.71 exercise price, giving the right to buy 292 shares of common stock. The options were granted at no cost and are held directly, with 292 derivative securities beneficially owned after the transaction. Vesting is contingent on Matsui continuing as a Service Provider, with all shares vesting on the earlier of the one-year anniversary of the January 30, 2026 vesting commencement date or the day before the next annual stockholder meeting following that date.
Artelo Biosciences, Inc. director Blayney Douglas received an award of stock options covering 292 shares of common stock at an exercise price of $1.71 per share. The options expire on January 30, 2036 and are held directly.
According to the grant terms, all 292 option shares vest in full if Douglas continues as a service provider until the earlier of the one-year anniversary of the vesting commencement date of January 30, 2026 or the day before the next annual stockholder meeting following that date. After this grant, he beneficially owns 292 derivative securities.
Artelo Biosciences director Emanuele Robert Martin received a small stock option grant. On January 30, 2026, he was awarded options to buy 292 shares of Artelo Biosciences common stock at an exercise price of $1.71 per share, expiring on January 30, 2036.
According to the terms, all 292 options vest in a single tranche, provided he continues as a service provider. Vesting occurs on the earlier of the one-year anniversary of the vesting commencement date of January 30, 2026, or the day before the next annual stockholder meeting following that date.
Artelo Biosciences director Kelly Steven received a new stock option grant. On January 30, 2026, Steven was awarded stock options to purchase 292 shares of Artelo Biosciences common stock at an exercise price of $1.71 per share, with no purchase price for the option itself.
The options vest in full if Steven continues as a service provider until the earlier of the one-year anniversary of the January 30, 2026 vesting commencement date or the day before the company’s next annual stockholder meeting after that date. After this grant, Steven beneficially owns 292 derivative securities directly.
Artelo Biosciences director Tamara A. Favorito reported a new stock option grant on Common Stock. On January 30, 2026, she was awarded stock options to purchase 292 shares at a conversion or exercise price of $1.71 per share.
All 292 options vest in full once, subject to her continuing as a service provider, on the earlier of the one-year anniversary of the January 30, 2026 vesting commencement date or the day before the next annual stockholder meeting following that date. After this grant, she beneficially owns 292 derivative securities directly.
Artelo Biosciences director Gregory Reyes received a small stock option grant. On January 30, 2026, he was awarded options to buy 292 shares of Artelo Biosciences common stock at an exercise price of $1.71 per share, held directly. These options vest 100% on the earlier of January 30, 2027 or the day before the next annual shareholder meeting, as long as he continues serving the company.
ARTELO BIOSCIENCES, INC. reported that its Chief Financial Officer, Mark Edward Spring, received a grant of stock options on January 29, 2026. The grant covers 36,391 stock options with an exercise price of $1.68 per share.
These options vest over four years, starting from a vesting commencement date of January 1, 2026. One forty-eighth of the option shares vests each month, so the award becomes fully vested on the four-year anniversary of that commencement date, as long as he continues as a service provider.
Artelo Biosciences reported a Form 4 insider transaction for President, CEO, CFO, Treasurer and Secretary Gregory D. Gorgas. He was granted 154,713 stock options on January 29, 2026 with an exercise price of $1.68 per share and expiration on January 29, 2036.
These options vest in equal monthly installments, with 1/48 of the shares vesting each month starting from a vesting commencement date of January 1, 2026, so long as he continues as a service provider. The entire grant is scheduled to be fully vested after four years.